重要内容提示： 证券代码：688189 证券简称：南新制药 公告编号：2025-028 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 265,516股 | | 累计已回购股 ...

Meeting Overview - The shareholders' meeting of Hunan Nanxin Pharmaceutical Co., Ltd. was held on June 13, 2025, in Guangzhou, Guangdong Province [1]. - The meeting was presided over by Chairman Zhang Shixi and utilized a combination of on-site and online voting methods [1]. Attendance and Voting - A total of 56 ordinary shareholders attended the meeting, holding 80,977,423 voting rights, which represents 29.6961% of the company's total voting rights [1]. - The voting results showed a strong majority in favor of the proposals, with ordinary shareholders voting 98.1570% in favor of the first resolution [2]. Resolutions Passed - Multiple resolutions were passed during the meeting, including: - The proposal for the company to provide guarantees for its subsidiaries [3]. - The profit distribution proposal for the year 2024 [3]. - The proposal to purchase directors and supervisors' liability insurance [3]. - The proposal to cancel a subsidiary [3]. - The proposal to use excess raised funds to permanently supplement working capital [3]. Legal Compliance - The meeting's procedures, including the qualifications of attendees and the voting process, were confirmed to be in compliance with legal regulations and the company's articles of association [3].

证券代码：688189 证券简称：南新制药 公告编号：2025-027 湖南南新制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 13 日 （二） 股东大会召开的地点：广东省广州市黄埔区开源大道 196 号广州南新制 药有限公司 313 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 56 | | --- | --- | | 普通股股东人数 | 56 | | 2、出席会议的股东所持有的表决权数量 | 80,977,423 | | 普通股股东所持有表决权数量 | 80,977,423 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 29.6961 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 29.6 ...

北京大成(广州)律师事务所 关于湖南南新制药股份有限公司 2024 年年度股东大会的 法律意见书 大成 DENTONS 大成 is Dentons' Preferred Law Firm in China. guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623 ） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 十三十成(广州) 广州市手河区珠江新城珠江东路 6 北京大成(广州)律师事务所 关于湖南南新制药股份有限公司 2024 年年度股东大会法律意见书 致:湖南南新制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》等法律、法规和其他有关规范性文件的要求,北京大成（广州）律 师事务所(以下简 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-026 湖南南新制药股份有限公司 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 142,114股 | | 累计已回购股数占总股本比例 | 0.05% | | 累计已回购金额 | 1,003,764.13元 | | 实际回购价格区间 | 7.02元/股~7.11元/股 | 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十 ...

Core Viewpoint - Nanjing Pharmaceutical (688189) is expanding its marketing network and product offerings in response to market demands, particularly in the flu treatment sector, while also initiating a share buyback program to enhance shareholder value [1][2][3] Group 1: Company Performance - As of May 30, 2025, Nanjing Pharmaceutical's stock closed at 7.06 yuan, with a 1.0% increase, a turnover rate of 3.09%, a trading volume of 84,700 shares, and a transaction value of 60.0036 million yuan [1] - On the same day, the net inflow of main funds was 6.1534 million yuan, while retail investors experienced a net outflow of 6.5781 million yuan [3] Group 2: Share Buyback Announcement - The company announced its first share buyback on May 30, 2025, repurchasing 142,114 shares, which is 0.05% of the total share capital of 274.4 million shares, at a total cost of approximately 1,003,764.13 yuan [2][3] - The buyback was approved during the board meeting on April 28, 2025, with a planned budget of between 10 million and 20 million yuan, and a maximum buyback price set at 9.53 yuan per share, to be completed within 12 months [2]

证券代码：688189 证券简称：南新制药 公告编号：2025-025 湖南南新制药股份有限公司 二、首次实施回购股份的基本情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次回购股份情况公告如下： 2025 年 5 月 30 日，公司以集中竞价交易方式首次回购公司股份 142,114 股， 占公司总股本 274,400,000 股的比例为 0.05%，回购成交的最高价为 7.11 元/股， 最低价为 7.02 元/股，支付的资金总额为人民币 1,003,764.13 元（不含印花税、 交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 三、其他事项 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1, ...

南新制药公告，公司于2025年5月30日以集中竞价交易方式首次回购股份14.21万股，占公司总股本2.74 亿股的0.05%，回购价格区间为7.02元/股至7.11元/股，累计使用资金100.38万元(不含交易费用)。此次 回购符合相关法律法规及公司回购方案要求，旨在实施股权激励或员工持股计划。 ...

Core Viewpoint - Nanjing New Pharmaceutical Co., Ltd. has announced multiple delays in its fundraising projects, particularly the "Marketing Channel Network Upgrade Project," which has been postponed to December 31, 2026, indicating ongoing challenges in project execution and market competition [1][3][4]. Group 1: Project Delays - The "Marketing Channel Network Upgrade Project" was initially set to be operational by June 30, 2025, but has now been delayed by an additional 18 months [1][3]. - The project aims to establish 8 new offices and upgrade 22 existing ones, with a total investment of 120 million yuan [2]. - The delays are attributed to macroeconomic conditions, industry policies, and a reduced need for new offices due to strategic adjustments [3][4]. Group 2: Termination of Projects - The company has terminated the "Palivizumab Dry Powder Inhalation Project" and redirected the remaining funds of 43.97 million yuan to the "Palivizumab Inhalation Solution Project" [4][5]. - The "Palivizumab Inhalation Solution Project" has also been delayed to December 31, 2026, with an increased funding allocation of 214 million yuan [4][6]. Group 3: Financial Performance - Nanjing New Pharmaceutical has faced significant financial challenges, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, representing a decrease of over 70% [8]. - The company has reported net losses in all years since its IPO, except for the first year, with a net profit of 128 million yuan in 2020 turning into a loss of 357 million yuan in 2024 [8]. - In Q1 2025, the company reported a revenue drop of 70.21% year-on-year, primarily due to lower market demand for antiviral products and price reductions [8]. Group 4: Market Strategy - The company has adopted a price reduction strategy to maintain market share in the competitive antiviral market, with a 43.51% price cut on its core product, Palivizumab, in 2023 [7]. - Despite these efforts, the declining sales and increased competition have not improved the company's financial situation [7][8].

以抗流感药物为核心产品的南新制药(688189)，日前公告IPO募投项目延期。当前，南新制药不仅营收 下滑，亏损显著增加，核心产品亦面临激烈市场竞争。 南新制药5月24日公告称，原定2025年6月30日完成的"营销渠道网络升级建设项目"，预计延期到2026年 12月31日，比原定计划延后18个月时间。南新制药称，受宏观经济环境和医药行业政策等影响，综合考 虑成本投入、产品管线丰富度等因素，公司及时调整和优化销售策略，对在特定省市建立办事处的实际 需求大幅减少。 位于湖南浏阳的南新制药2020年3月上市，控股股东为湖南省国资委所属湖南医药发展投资集团有限公 司，公司也是湖南省首家登陆科创板的药企。南新制药IPO时，实际募集资金净额为人民币11.3亿元， 募集资金计划投向创新药研发、营销渠道网络升级建设、补充流动资金等项目。 此外，南新制药另有3个创新药、2个改良型新药在研。在仿制药产品线方面，公司在售产品包括辛伐他 汀分散片、头孢克洛胶囊头孢呋辛酯分散片、乳酸环丙沙星氯化钠注射液、复方布洛芬片等较为成熟的 仿制药。 上市首年2020年，尽管受疫情等不利因素影响，南新制药实现营业收入10.29亿元，归属净利润1. ...